ArticleCase reports in dermatology
Tofacitinib in Overlapping Autoimmune and Autoinflammatory Disorders: A Case Report of a Dual Graham-Little-Piccardi-Lasseur Syndrome and Hidradenitis Suppurativa.
Article in Case reports in dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Graham-Little-Piccardi-Lassueur Syndrome (GLPLS) is an autoimmune disorder characterized by a triad of cicatricial alopecia of the scalp, non-cicatricial alopecia, and follicular eruptions in the axillae and groin. Immune system dysregulation can contribute to associations with other inflammatory diseases. Case Presentation: Here, we present a female patient with a history of scalp hair loss and follicular purulent lesions on the trunk. Biopsies from three sample sites on the scalp and trunk confirmed the diagnosis of both GLPLS and hidradenitis suppurativa (HS). Due to a limited response to previous treatments, including immunosuppressants and antibiotics, the patient was considered for tofacitinib 5 mg twice daily. After 6 months of treatment, improvement in hair loss and resolution of trunk lesions were observed. Additionally, no recurrence or adverse events were noted during a 2-year follow-up. Conclusion: This case report underscores the likelihood of co-occurrence of two hard-to-treat disorders, both with autoimmune and autoinflammatory basis, and significant improvement of both diseases with a Janus kinase inhibitor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.